指南与共识乳腺癌

乳腺癌患者的胚系检测:ASCO-肿瘤外科学会指南

Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.
指南 / 共识 · J Clin Oncol · 2024-01-04

ASCO与肿瘤外科学会(SSO)专家组基于系统综述和正式共识流程制定乳腺癌胚系突变检测推荐。推荐对所有≤65岁新诊断乳腺癌患者及部分>65岁患者提供BRCA1/2检测,并对复发、第二原发癌及高/中 penetrance 基因检测给出条件。

要点

  • 所有≤65岁新诊断乳腺癌患者应提供BRCA1/2检测,>65岁者根据个人史、家族史、 ancestry或PARP抑制剂资格选择。
  • 复发乳腺癌且为PARP抑制剂候选者应提供BRCA1/2检测,无论家族史。
  • 意义未明变异不应影响管理,应随访再分类;检测前需充分知情同意。

核心结论

  • ASCO-SSO专家组基于系统综述和正式共识流程,为乳腺癌患者胚系突变检测制定推荐。

研究设计与样本

  • ASCO-肿瘤外科学会(SSO)专家组召开会议,基于系统综述和正式共识流程制定推荐。
  • 胚系突变检测推荐有47篇文章符合纳入标准,遗传咨询推荐有18篇符合纳入标准。

主要发现

  • 47篇文章符合胚系突变检测推荐的纳入标准;18篇符合遗传咨询推荐的纳入标准。

关键数值与推荐

  • 应为所有新诊断≤65岁乳腺癌患者提供BRCA1/2突变检测,>65岁患者根据个人史、家族史、 ancestry或聚(ADP-核糖)聚合酶(PARP)抑制剂治疗资格选择性提供。
  • 所有复发乳腺癌且为PARP抑制剂治疗候选者的患者均应提供BRCA1/2检测,无论家族史。
  • 应为发生同侧或对侧第二原发癌的女性提供BRCA1/2检测。
  • 既往乳腺癌史且无活动性疾病者,若诊断时≤65岁应提供检测;诊断时>65岁者若检测可提供个人和家族风险信息则选择性提供。
  • 应为主要高外显率癌症易感基因(BRCA1/2以外)有支持性家族史者提供检测;中外显率基因检测可在必要时提供以评估个人和家族癌症风险。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To develop recommendations for germline mutation testing for patients with breast cancer. METHODS: An ASCO-Society of Surgical Oncology (SSO) panel convened to develop recommendations based on a systematic review and formal consensus process. RESULTS: Forty-seven articles met eligibility criteria for the germline mutation testing recommendations; 18 for the genetic counseling recommendations. RECOMMENDATIONS: BRCA1/2 mutation testing should be offered to all newly diagnosed patients with breast cancer ≤65 years and select patients >65 years based on personal history, family history, ancestry, or eligibility for poly(ADP-ribose) polymerase (PARP) inhibitor therapy. All patients with recurrent breast cancer who are candidates for PARP inhibitor therapy should be offered BRCA1/2 testing, regardless of family history. BRCA1/2 testing should be offered to women who develop a second primary cancer in the ipsilateral or contralateral breast. For patients with prior history of breast cancer and without active disease, testing should be offered to patients diagnosed ≤65 years and selectively in patients diagnosed after 65 years, if it will inform personal and family risk. Testing for high-penetrance cancer susceptibility genes beyond BRCA1/2 should be offered to those with supportive family histories; testing for moderate-penetrance genes may be offered if necessary to inform personal and family cancer risk. Patients should be provided enough pretest information for informed consent; those with pathogenic variants should receive individualized post-test counseling. Variants of uncertain significance should not impact management, and patients with such variants should be followed for reclassification. Referral to providers experienced in clinical cancer genetics may help facilitate patient selection and interpretation of expanded testing, and provide counseling of individuals without pathogenic germline variants but with significant family history.Additional information is available at www.asco.org/breast-cancer-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bedrosian I, Somerfield MR, Achatz MI, et al. Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol. 2024. PMID: 38175972. doi:10.1200/JCO.23.02225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。